TNFRSF9 and non-Hodgkin lymphoma: ADG106, a fully human IgG4 mAb that stimulates 4-1BB on T and NK cells, is being studied as monotherapy in a phase I clinical trial in patients with advanced solid malignancies and relapsed/refractory non-Hodgkin’s lymphoma (NHL) (NCT03802955).